Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 20/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403620 | 0.93 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL6399220 | 0.88 | CHRNA7 (0.43) | CHRNA7KCNH2CHRNA1CYP3A4CHRNB2 | |
| SCHEMBL6399647 | 0.85 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL6209060 | 0.84 | QPCT (0.38) | CHRNA7KCNH2 | |
| SCHEMBL6230975 | 0.84 | CHRNA7 (0.34) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL6398977 | 0.84 | KDR (0.34) | CHRNA7KCNH2 | |
| SCHEMBL6205699 | 0.84 | MAP2K1 (0.37) | CHRNA7KCNH2CYP3A4 | |
| SCHEMBL6207255 | 0.83 | CHRNA7 (0.33) | CHRNA7KCNH2CHRNA1CYP3A4CHRNB2 | |
| SCHEMBL6207867 | 0.82 | CHRNA7 (0.33) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL6205441 | 0.82 | CHRNA7 (0.46) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | CHRNA7 4667/4885KCNH2 3852/4885CHRNA1 4381/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | CHRNA7 3909/4885KCNH2 3635/4885CHRNA1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.